
News|Articles|November 5, 2025
Conference Preview: NASPGHAN Annual Meeting 2025
Author(s)Joshua Fitch
Fact checked by: HCPLive staff
This preview of the 2025 NASPGHAN Annual Meeting highlights sessions and expert discussions on pediatric gastroenterology, hepatology, and nutrition covered by HCPLive.
Advertisement
Advertisement
The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) is holding its Annual Meeting from November 5–8, 2025, at the Sheraton Grand Chicago in Chicago, Illinois. Over the course of this four-day conference, pediatric gastroenterologists, hepatologists, nutrition specialists, and leading experts will gather to share the latest data, clinical updates, and evidence-based discussions across gastrointestinal, liver, and nutritional disorders in children.
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.
Advertisement
Advertisement

